Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Cited by (1,021)

Items 401–500 of 1,021

1. Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
   Hiu Wing Cheung, Jinyan Du, Jesse S. Boehm, Frank He, Barbara A. Weir, Xiaoxing Wang, Mohit Butaney, Lecia Van Dam Sequist, Biao Luo, Jeffrey A. Engelman et al. · 2011 · Cancer Discovery
2. Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
   Matias Casás‐Selves, Jihye Kim, Zhiyong Zhang, Barbara A. Helfrich, Dexiang Gao, Christopher C. Porter, Hannah A. Scarborough, Paul A. Bunn, Daniel C. F. Chan, Aik Choon Tan et al. · 2012 · Cancer Research
3. Small cell lung cancer (SCLC): no treatment advances in recent years.
   Filippos Koinis, Athanasios Panayotis Kotsakis, Vasileios Georgoulias · 2016 · Europe PMC (PubMed Central)
4. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
   Mahaveer Singh, Hemant R. Jadhav · 2017 · Drug Discovery Today
5. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
   Melissa Lynne Johnson, Helena Alexandra Yu, Eric M. Hart, Bing Bing Weitner, ALFRED W. RADEMAKER, Jyoti D. Patel, Mark G. Kris, Gregory J. Riely · 2015 · Journal of Clinical Oncology
6. EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
   Jean‐Charles Soria, Tony S.K. Mok, Federico Cappuzzo, Pasi Antero Janne · 2011 · Cancer Treatment Reviews
7. EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
   Alberto Antonicelli, Stefano Cafarotti, Alice Indini, Alessio Galli, Andrea Russo, Alfredo Cesario, Filippo Lococo, Patrizia Russo, Alberto Franco Mainini, Luca Giuseppe Bonifati et al. · 2013 · International Journal of Medical Sciences
8. EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib
   Jean‐Nicolas Gallant, Jonathan H. Sheehan, Timothy M. Shaver, Mark Bailey, Doron Lipson, Raghu Chandramohan, Monica Red Brewer, Sally Jane York, Mark G. Kris, Jennifer A. Pietenpol et al. · 2015 · Cancer Discovery
9. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
   Kurtis D. Davies, Sakshi Mahale, David P. Astling, Dara L. Aisner, Anh Tuan Le, Trista K. Hinz, Aria Vaishnavi, Paul A. Bunn, Lynn E. Heasley, Aik Choon Tan et al. · 2013 · PLoS ONE
10. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer
    Ahnah Song, Tae Min Kim, Dong‐Wan Kim, Soyeon Kim, Bhumsuk Keam, Se‐Hoon Lee, Dae Seog Heo · 2015 · Clinical Cancer Research
11. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
    Jake June-Koo Lee, Jong Yeon Shin, Su‐Hyeon Kim, S. Lee, Connor C. Park, J. Y. Kim, Y. Koh, Bhumsuk Keam, Hye Sook Min, T.M. Kim et al. · 2013 · Annals of Oncology
12. LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
    Xinyin Liu, Xiyi Lu, Fuxi Zhen, Shidai Jin, Tongfu Yu, Quan Zhu, Wei Ting Wang, Kun Xu, Jiaqi Yao, Renhua Guo · 2019 · Molecular Therapy — Nucleic Acids
13. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
    Zheng-Hai Tang, Jin‐Jian Lu · 2018 · Cancer Letters
14. Role of epidermal growth factor receptor in lung cancer and targeted therapies.
    Tiecheng Liu, Xin Jin, Yan Wang, Ke Wang · 2017 · Europe PMC (PubMed Central)
15. Molecular Pathology of Primary Non-small Cell Lung Cancer
    David Ilan Suster, Mari A. Mino-Kenudson · 2020 · Archives of Medical Research
16. Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
    Nathaniel W. Mabe, Min Huang, Guillermo Nicolás Dalton, Gabriela Alexe, Daniel A. Schaefer, Anna C. Geraghty, Amanda L. Robichaud, Amy Saur Conway, Delan Khalid, Marius Marc-Daniel Mader et al. · 2022 · Nature Cancer
17. Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
    Singh, Mallika, Murriel, Christopher L., Johnson, Leisa · 2012 · Cancer Research
18. A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
    Thomas A. Hensing, Apoorva Chawla, Rishi Batra, Ravi Salgia · 2013 · Advances in experimental medicine and biology
19. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
    Yuan Cheng, Tao Zhang, Qing Xu · 2021 · MedComm
20. TGF-β: An emerging player in drug resistance
    Brunen, Diede, Willems, Stefan, Kellner, Udo, Midgley, Rachel, Simon, Iris, Bernards, Rene · 2013 · Cell Cycle
21. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
    Susan E. Jorge, Susumu S. Kobayashi, Daniel Botelho Costa · 2014 · Brazilian Journal of Medical and Biological Research
22. Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer
    Chandan Kanta Das, Aditya Parekh, Pratap Kumar Parida, Sujit K. Bhutia, Mahitosh Mandal · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
23. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
    Ken Suzawa, Michael David Offin, Daniel Lu, Christopher Kurzatkowski, Morana Vojnic, Roger S. Smith, Joshua K. Sabari, Huichun Tai, Marissa S. Mattar, Inna Khodos et al. · 2018 · Clinical Cancer Research
24. Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
    Tatsuya Yoshida, Genichiro Ishii, Kōichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu et al. · 2014 · Clinical Cancer Research
25. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
    Andrea Weiss, Xianting Ding, Judy R. Van Beijnum B, Ieong Wong, Tse J. Wong, Robert H. Berndsen, Olivier Dormond, Marchien G. Dallinga, Li Shen, Reinier O. Schlingemann et al. · 2015 · Angiogenesis
26. PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin
    Patrick Leo Apopa, Lisa Alley, Rosalind B. Penney, Konstantinos Arnaoutakis, Matthew A. Steliga, Susan Jeffus, Emine Bircan, Banu Gopalan, Jing Jin, Preecha Patumcharoenpol et al. · 2018 · Frontiers in Microbiology
27. EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
    Jia, Yong, Juarez, Jose, Li, Jie, Manuia, Mari, Niederst, Matthew J., Tompkins, Celin, Timple, Noelito, Vaillancourt, Mei-Ting, Pferdekamper, AnneMarie Culazzo, Lockerman, Elizabeth L. et al. · 2016 · Cancer Research
28. Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy
    H. Al-Halabi, Karl Sayegh, Subba R. Digamurthy, Andrzej Niemierko, Zofia Piotrowska, Henning Willers, Lecia Van Dam Sequist · 2015 · Journal of Thoracic Oncology
29. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression
    Yijun Gao, Wenjing Zhang, Xiangkun Han, Fuming Li, Xujun Wang, Rui Wang, Zhaoyuan Fang, Xinyuan Tong, Shun Yao, Fei Li et al. · 2014 · Nature Communications
30. Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
    Reinhard Buettner, Jürgen Wolf, Roman Kurt Thomas · 2013 · Journal of Clinical Oncology
31. Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology
    Emma Norkowski, Maria‐Rosa Ghigna, Ludovic Lacroix, Thierry Le Chevalier, Élie Fadel, Philippe Dartevelle, Peter Dorfmüller, Vincent de Montpréville · 2013 · Journal of Thoracic Oncology
32. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
    Katherine R. Amato, Shan Wang, Li Tan, Andrew K. Hastings, Wenqiang Song, Christine Marie Lovly, Catherine Belle Meador, Fei Ye, Lu Wang, Justin Micah Balko et al. · 2016 · Cancer Research
33. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer
    Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu et al. · 2020 · Clinical Cancer Research
34. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
    Mark Agulnik, Nelson, Ziehr, J R Johnson · 2013 · OncoTargets and Therapy
35. Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
    Rodrigo Dienstmann, Jordi Ahnert Rodon, Jordi Barretina, Josep M. Tabernero · 2013 · Journal of Clinical Oncology
36. ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
    D N Debruyne, Namrata Bhatnagar, B Sharma, William Luther, N F Moore, NK Cheung, Nathanael S. Gray, R E George · 2015 · Oncogene
37. Molecular pathology of lung cancer: current status and perspectives
    Felicitas Oberndorfer, Leonhard Müllauer · 2017 · Current Opinion in Oncology
38. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
    Yuankai Shi, Xingsheng Hu, Shucai Zhang, Dongqing Lv, Lin Wu, Qitao Yu, Yiping Zhang, Li Liu, Xiang Wang, Ying Cheng et al. · 2021 · The Lancet Respiratory Medicine
39. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
    Jong‐Mu Sun, Myung‐Ju Ahn, Yoon‐La Choi, Jin Seok Ahn, Keunchil Park · 2013 · Lung Cancer
40. A Novel Classification of Lung Cancer into Molecular Subtypes
    Lisandra E. West, Smruti J. Vidwans, Nicholas Paul Campbell, Jeff Shrager, George R. Simon, Raphael Bueno, Phillip A. Dennis, Gregory A. Otterson, Ravi Salgia · 2012 · PLoS ONE
41. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012
    Fred R. Hirsch, Pasi Antero Janne, Wilfried Eberhardt, Federico Cappuzzo, N. Thatcher, Robert Pirker, Hak Choy, Edward S. Kim, Luis G Paz-Ares, David R. Gandara et al. · 2013 · Journal of Thoracic Oncology
42. Molecular Pathology of Non–Small Cell Lung Cancer
    Dara L. Aisner, Carrie B. Marshall · 2012 · American Journal of Clinical Pathology
43. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Current Cancer Drug Targets
44. Clonal <i>MET</i> Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
    Lai, Gillianne G.Y., Lim, Tse Hui, Lim, John, Liew, Perry J.R., Kwang, Xue Lin, Nahar, Rahul, Aung, Zaw Win, Takano, Angela, Lee, Yin Yeng, Lau, Dawn P.X. et al. · 2019 · Journal of Clinical Oncology
45. Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
    Sharmin Akter, Rajesh Madhuvilakku, Anik Kumar Kar, Irin Sultana Nila, Pengda Liu, Hiroyuki Inuzuka, Wenyi Wei, Yonggeun Hong · 2026 · Signal Transduction and Targeted Therapy
46. TGFβ pathway inhibition in the treatment of non-small cell lung cancer
    Pınar Ö. Eser, Pasi Antero Janne · 2017 · Pharmacology & Therapeutics
47. Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing
    Shinji Kohsaka, Mark P. Petronczki, Flavio Solca, Makoto Maemondo · 2018 · Future Oncology
48. Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
    Harvey, R Donald, Adams, Val R, Beardslee, Tyler, Medina, Patrick · 2020 · Journal of Oncology Pharmacy Practice
49. Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
    Sacha I. Rothschild · 2015 · Cancers
50. The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
    Priyanka H. Patel, David A. Palma, Fiona McDonald, Alison Claire Tree · 2019 · Clinical Oncology
51. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
    Catherine Belle Meador, Aaron N. Hata · 2020 · Pharmacology & Therapeutics
52. Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling
    Solveigh C. Koeberle, Anna Patricia Kipp, Hermann Stuppner, Andreas Koeberle · 2023 · Medicinal Research Reviews
53. Lineage-specific intolerance to oncogenic drivers restricts histological transformation
    Eric E. Gardner, Ethan M. Earlie, Kate Li, Jerin Thomas, Melissa J. Hubisz, Benjamin D. Stein, Chen Zhang, Lewis C. Cantley, Ashley Marie Laughney, HAROLD E. VARMUS · 2024 · Science
54. Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation
    Hyeong Ryul Kim, Woo Sung Kim, Yun Jung Choi, Chang‐Min Choi, Jin Kyung Rho, Jae Cheol Lee · 2013 · Molecular Oncology
55. Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer
    Shirish M. Gadgeel, Antoinette J. Wozniak · 2013 · Clinical Lung Cancer
56. Signaling cross-talk in the resistance to HER family receptor targeted therapy
    Hirohito Yamaguchi, S.H. Chang, J L Hsu, Mien‐Chie Hung · 2013 · Oncogene
57. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
    Jingsi Dong, Bingjie Li, Dan Chi-Chia Lin, Qinghua Zhou, Depei Huang · 2019 · Frontiers in Pharmacology
58. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
    David König, Spasenija Savic Prince, Sacha I. Rothschild · 2021 · Cancers
59. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
    Julian Engel, André Richters, Matthäus Getlik, Stefano Tomassi, Marina Keul, Martin Termathe, Jonas Lategahn, Christian Becker, Svenja C. Mayer‐Wrangowski, Christian Grütter et al. · 2015 · Journal of Medicinal Chemistry
60. Building a Personalized Medicine Infrastructure at a Major Cancer Center
    Funda Meric‐Bernstam, Carol J. Farhangfar, John M. Mendelsohn, Gordon Brent Mills · 2013 · Journal of Clinical Oncology
61. Prospects for new lung cancer treatments that target EMT signaling
    Yuji Otsuki, Hideyuki Saya, Yoshimi Arima · 2017 · Developmental Dynamics
62. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer
    Ji Li, Peter S. Choi, Christine Louise Chaffer, Katherine Labella, Justin H Hwang, Andrew O. Giacomelli, Jong Wook Kim, Nina Ilić, John G. Doench, Seav Huong Ly et al. · 2018 · eLife
63. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    Jing Gao, Hao-Ran Li, C. Jin, Jingwei Jiang, Jian‐Yong Ding · 2019 · Clinical & Translational Oncology
64. Targeted therapies: how personal should we go?
    Miriam Martini, Loredana Vecchione, Salvatore Siena, Sabine Tejpar, Alberto Bardelli · 2011 · Nature Reviews Clinical Oncology
65. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
    Kang-Seo Park, Mark A. Raffeld, Yong Wha Moon, Liqiang Xi, Caterina Bianco, Trung C. Pham, Liam C. Lee, Tetsuya Mitsudomi, Yasushi Yatabe, Isamu Okamoto et al. · 2014 · Journal of Clinical Investigation
66. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma
    Erin Stewart, Céline Mascaux, Nhu‐An Pham, Shingo Sakashita, Jenna R. Sykes, Lucia Kim, Naoki Yanagawa, Ghassan Allo, Kota Ishizawa, Dennis Y.Q. Wang et al. · 2015 · Journal of Clinical Oncology
67. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
68. Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy
    Shyamala Maheswaran, Daniel A. Haber · 2015 · Cancer Research
69. Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
    Namrata Bora-Singhal, Deepak Perumal, Jonathan V. Nguyen, Srikumar Chellappan · 2015 · Neoplasia
70. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
    Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Akihiro Yoshimura, Shinsuke Shiotsu, Satoshi Watanabe, Toshiaki Kikuchi, Kazuki Hirose, Yutaka Kubota, Yusuke Chihara et al. · 2019 · Cancer Medicine
71. Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
    Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah O. Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka et al. · 2021 · Cancer Discovery
72. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
    Helmout Modjtahedi, Byoung Chul Cho, Martin Christian Michel, Flavio Solca · 2014 · Naunyn-Schmiedeberg s Archives of Pharmacology
73. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Kristine Raaby Jakobsen, Christina Demuth, Boe Sandahl Sørensen, Anders Lade Nielsen · 2016 · Translational Lung Cancer Research
74. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going
    Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Valeria Smiroldo, M. Picciotto, Mariangela Zanghì, Christian Diego Rolfo, Vincenzo Adamo · 2017 · Critical Reviews in Oncology/Hematology
75. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
    Deborah R. Caswell, Philippe Gui, Manasi K. Mayekar, Emily K. Law, Oriol Pich, Chris Bailey, Jesse Boumelha, Daniel Lucas Kerr, Collin Michael Blakely, Tadashi Manabe et al. · 2023 · Nature Genetics
76. Targeting EGFR in Lung Cancer: Current Standards and Developments
    Díaz-Serrano, Asunción, Gella, Pablo, Jiménez, Elisabeth, Zugazagoitia, Jon, Paz-Ares Rodríguez, Luis · 2018 · Drugs
77. BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
    Eftychia Oikonomou, Evangelos Koustas, Maria Goulielmaki, Alexander Pintzas · 2014 · Oncotarget
78. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
    Masahiko Yanagita, Amanda J. Redig, Cloud Peter Paweletz, Suzanne Eleanor Dahlberg, Allison O’Connell, Nora B. Feeney, Myriam Taibi, David H. Boucher, Geoffrey R. Oxnard, Bruce Evan Johnson et al. · 2016 · Clinical Cancer Research
79. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
    Eng, Juliana, Woo, Kaitlin M., Sima, Camelia S., Plodkowski, Andrew, Hellmann, Matthew D., Chaft, Jamie E., Kris, Mark G., Arcila, Maria E., Ladanyi, Marc, Drilon, Alexander · 2015 · Journal of Thoracic Oncology
80. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
    Hui Pan, Tao Jiang, Ningning Cheng, Qi Wang, Shengxiang Ren, Xuefei Li, Chao Zhao, Limin Zhang, Weijing Cai, Caicun Zhou · 2016 · Oncotarget
81. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
    Monique B. Nilsson, Yan Yang, Simon Heeke, Sonia A. Patel, Alissa Poteete, Hibiki Udagawa, Yasir Y. Elamin, César A. Moran, Yukie Kashima, Thiruvengadam Arumugam et al. · 2023 · Cancer Cell
82. Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer
    Takeshi Yoshida, Guolin Zhang, Matthew A. Smith, Alex S. Lopez, Yun Bai, Jiannong Li, Bin Fang, John M. Koomen, Bhupendra Rawal, Kate J. Fisher et al. · 2014 · Clinical Cancer Research
83. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
    Yuting Sun, Brooke A. Meyers, Barbara Czakó, Paul G. Leonard, Faika Mseeh, Angela L. Harris, Qi Wu, Sarah B. Johnson, Connor A. Parker, Jason B. Cross et al. · 2020 · Cancer Research
84. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
    Damien Reita, Lucile Pabst, Erwan Pencreach, Éric Guérin, Laurent Dano, Valérie Rimelen, Anne‐Claire Voegeli, Laurent D. Vallat, Céline Mascaux, Michèle Beau‐Faller · 2021 · Cancers
85. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
    Minari, R., Bordi, P., Del Re, M., Facchinetti, F., Mazzoni, F., Barbieri, F., Camerini, A., Comin, C.E., Gnetti, L., Azzoni, C. et al. · 2018 · Lung Cancer
86. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A. · 2016 · Lung Cancer
87. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
    Mallika Singh, Napoleone Ferrara · 2012 · Nature Biotechnology
88. Melatonin as a potential anticarcinogen for non-small-cell lung cancer
    Zhiqiang Ma, Yang Yang, Chongxi Fan, Jing Han, Dongjin Wang, Shouyin Di, Wei Hu, Dong Liu, Xiaofei Li, Russel Joseph Reiter et al. · 2016 · Oncotarget
89. Lineage Plasticity in Cancer Progression and Treatment
    Clémentine Le Magnen, Michael M. Shen, Cory T. Abate-Shen · 2017 · Annual Review of Cancer Biology
90. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
    Maximilian Johannes Hochmair, Anna Buder, Sophia Schwab, Otto Chris Burghuber, Helmut Prosch, Wolfgang Hilbe, Agnieszka Cseh, Richard Fritz, Martin Filipits · 2018 · Targeted Oncology
91. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
    Kenichi Nishie, Tomoya Kawaguchi, Akihiro Tamiya, Tomoyasu Mimori, Naoko Takeuchi, Yoshinobu Matsuda, Naoki Omachi, Kazuhiro Asami, Kyoichi Okishio, Shinji Atagi et al. · 2012 · Journal of Thoracic Oncology
92. Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
    Lu Xu, Eiki Kikuchi, Chunxiao Xu, Hiromichi Ebi, Dalia Ercan, Katherine A. Cheng, Robert F. Padera, Jeffrey A. Engelman, Pasi Antero Janne, Geoffrey Ira Shapiro et al. · 2012 · Cancer Research
93. TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
    Nan Jing, Yuping Du, Xing Chen, Qifeng Bai, Yuxin Wang, Xinxin Zhang, Ning Zhu, Jing Zhang, Jianwen Hou, Qin Lin Wang et al. · 2014 · Molecular Cancer Therapeutics
94. miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives
    Mateusz Florczuk, Adam Szpechciński, Joanna Chorostowska‐Wynimko · 2017 · Targeted Oncology
95. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway
    Yuhong Lü, Yanfeng Liu, Sebastian Oeck, Gary J. Zhang, Alexander R. Schramm, Peter M. Glazer · 2020 · Cancer Research
96. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance
    Qiyao Zheng, Hui Dong, Jianshan Mo, Yi Zhang, Jie Huang, Shumin Ouyang, Shuo Shi, Kai Zhu, Xinming Qu, Wenhao Hu et al. · 2020 · Theranostics
97. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
    Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya et al. · 2021 · Clinical Cancer Research
98. Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
    Stefania Crucitta, Federico Cucchiara, Ron H.J. Mathijssen, Joaquı́n Mateo, Agnes Jager, Arjen Joosse, Antonio Passaro, Ilaria Attili, Iacopo Petrini, Ron HN van Schaik et al. · 2022 · Cancer Treatment Reviews
99. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
    Kenta Masui, Beatrice Gini, J. Wykosky, Ciro Zanca, Paul S. Mischel, Frank B. Furnari, Webster K. Cavenee · 2013 · Carcinogenesis
100. Optimizing outcomes in <i>EGFR</i> Mutation-Positive Nsclc: Which Tyrosine Kinase Inhibitor and When?
     Girard, Nicolas · 2018 · Future Oncology